Tubeimoside-1 induces TFEB-dependent lysosomal degradation of PD-L1 and promotes antitumor immunity by targeting mTOR

• Main Authors: Xiaojia Liu (Author), Mingxiao Yin (Author), Jingwen Dong (Author), Genxiang Mao (Author), Wenjian Min (Author), Zean Kuang (Author), Peng Yang (Author), Lu Liu (Author), Na Zhang (Author), Hongbin Deng (Author)
• Format: Book
• Published: Elsevier, 2021-10-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Programmed cell death ligand 1 (PD-L1)/programmed cell death protein 1 (PD-1) cascade is an effective therapeutic target for immune checkpoint blockade (ICB) therapy. Targeting PD-L1/PD-1 axis by small-molecule drug is an attractive approach to enhance antitumor immunity. Using flow cytometry-based...